Generic competition · all medicines · read 12 November 2026
Is there a generic of Carbidopa; Levodopa, and who makes it?
Carbidopa; Levodopa appears in 6 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 13 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 8.3 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Carbidopa; Levodopa appears in 6 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 13 generic makers listed as marketed across them.
- 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came 8.3 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Brand listed as marketed: Dhivy and Sinemet. 8 generic makers with 22 generic products listed as marketed; the first generic approval is dated 28 August 1992.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Dr Reddys Laboratories Sa | 28 August 1992 | 3 |
| Actavis Elizabeth Llc | 3 September 1993 | 3 |
| Sun Pharmaceutical Industries Ltd | 28 October 2008 | 3 |
| Pharmobedient Consulting Llc | 28 September 2009 | 1 |
| Sciegen Pharmaceuticals Inc | 7 May 2021 | 3 |
| Rubicon Research Ltd | 21 September 2022 | 3 |
| Aurobindo Pharma Ltd | 28 November 2022 | 3 |
| Ascent Pharmaceuticals Inc | 14 January 2025 | 3 |
Patents and exclusivities still listed
- 28 March 2039Patent 11819485
- 28 March 2039Patent 11439613
- 28 March 2039Patent 11033521 drug product
Tablet, Extended Release, Oral
Four or more generic makers listed
Every brand product here is listed as discontinued. 6 generic makers with 12 generic products listed as marketed; the first generic approval is dated 30 September 1999.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Mylan Pharmaceuticals Inc | 30 September 1999 | 2 |
| Impax Laboratories Inc | 14 May 2004 | 2 |
| Accord Healthcare Inc | 8 February 2013 | 2 |
| Alembic Pharmaceuticals Ltd | 5 June 2019 | 2 |
| Sciegen Pharmaceuticals Inc | 5 October 2021 | 2 |
| Rubicon Research Ltd | 4 June 2024 | 2 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Tablet, Orally Disintegrating, Oral
Generics listed, no brand listed
No brand application is listed. 2 generic makers with 6 generic products listed as marketed; the first generic approval is dated 27 August 2004.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Rising Pharma Holding Inc | 18 September 2008 | 3 |
| Sun Pharmaceutical Industries Ltd | 31 July 2009 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Capsule, Extended Release, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Crexont and Rytary. No generic is listed as marketed.
Patents and exclusivities still listed
- 7 August 2027Exclusivity NP Crexont
- 26 December 2028Patent 9089607 drug product
- 26 December 2028Patent 8377474 drug product
- 26 December 2028Patent 8454998 drug product
- 26 December 2028Patent 8557283 drug product
- 26 December 2028Patent 9901640 drug product
- 26 December 2028Patent 9533046 drug product
- 26 December 2028Patent 9463246 drug product
- 26 December 2028Patent 9089608 drug product
30 more patents are listed.
Tablet, For Suspension, Oral
Nothing listed as marketed
No brand application is listed. No generic is listed as marketed (3 generic products listed as discontinued).
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Suspension, Enteral
Brand listed, no generic listed as marketed
Brand listed as marketed: Duopa. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.